Mr. Speaker, multiple sclerosis is a devastating disease. It attacks the nervous system and affects people's vision, mobility, balance, and ability to maintain a memory. Because MS is progressive, its course is highly variable and unpredictable. The emotional, physical and financial drain on those who are affected and on their families is immeasurable.
Many Canadians living with MS have shared their personal stories on how the disease has led to a loss of their autonomy. Many members in the House have friends or family members who have multiple sclerosis and are aware of the hardship that comes with living with this disease. I know members will share my view that MS patients and their families show tremendous courage in the face of such a difficult illness.
Sadly, there is no cure for multiple sclerosis. Current treatment is geared toward managing the symptoms and slowing the disease's progression.
In 2009 Dr. Paolo Zamboni, who is based in Italy, suggested that chronic cerebrospinal venous insufficiency, or CCSVI, could be a main cause of MS. To treat this condition, he proposed a surgical procedure, venous angioplasty, which involves opening up the blocked veins in the neck of the patient. Dr. Zamboni's findings, and those of other studies on CCSVI, have raised the hopes of MS patients, patient groups and members of this House.
Unfortunately, despite the interest that greeted Dr. Zamboni's procedure, it is clear that there is no immediate procedure for treating MS.
There are many unanswered questions on the safety and efficacy of this proposed procedure. There is also some uncertainty about the relationship between CCSVI and MS.
I understand the motivation of those who argue that there is no need for further evaluation of the safety of this proposed MS procedure. Each of us wants to ensure the best possible solution for Canadians living with MS. That said, the government and we in this House have a moral and ethical obligation to work with the scientific and medical community and proceed only on the basis of the best medical and scientific evidence available to us right now.
The government is not alone in this view. According to the MS Society of Canada:
Adding clarity to the relationship between CCSVI and MS is essential in assisting people with MS [to] secure any treatment they may consider.
The MS Society goes on to say that:
Medical institutions and health care providers require research data confirming the validity, necessity and safety of any procedure they provide, and in their view, that data is not yet available as it relates to the relationship between CCSVI and MS.
Even the MS Society of Italy, where this procedure was developed, announced in June 2010 that it intends to support an epidemiological study of CCSVI.
In September 2010 the Canadian Medical Association concurred with CIHR when they stated:
The CMA concurs with the CIHR's position on the need for an evidence-based approach to the development of clinical trials of the recently proposed condition called “chronic cerebrospinal venous insufficiency (CCSVI).
Dr. Anthony Traboulsee, a neurologist with expertise in the diagnosis and management of MS, expressed this sentiment very clearly when quoted recently by the British Columbia Human Rights Tribunal.
Dr. Traboulsee is the medical director of the UBC Hospital MS program, the director of the MS clinical trials research group, the president of the Canadian Network of MS Clinics and serves on the CIHR's scientific expert working group on MS. In a November 2011 decision, the tribunal quoted Dr. Traboulsee as follows:
New theories and new treatment proposals are welcome. However, in my opinion, based on the evidence available--both published and unpublished--I cannot recommend or support the use of venous angioplasty or stenting of the veins that drain the brain and spinal cord in patients with MS.
It is clear that experts in Canada and around the world are advising caution on this matter. Being cautious, however, does not mean we are not moving forward.
As a surgeon myself, I appreciate both the need for caution for the safety of patients as well as the need to drive forward with new ideas and innovation. That is why in 2010, a full year before Bill C-280 was introduced, the CIHR set up a scientific expert working group to monitor and analyze research-based evidence on the MS/CCSVI issue.
At its meeting in June 2011, the CIHR's scientific expert working group decided that enough evidence was now available to move forward with a clinical trial on the safety and efficacy of the procedure proposed by Dr. Zamboni.
The following day, the Minister of Health acted quickly and asked CIHR to develop a call for proposals for the clinical trials on that procedure.
I am pleased to advise the House that the call for proposals is now posted on CIHR's website. A competitive and rigorous peer review process will be completed by CIHR to ensure that the successful proposals meet international standards for research excellence. This review will likely be completed by early 2012. The announcement of the research team selected for conducting the clinical trials will come shortly after that.
Several provinces and territories have expressed interest in working with the Government of Canada on setting up the national clinical trial. It is scientifically and medically important to respect the different steps involved in the selection and approval of the research proposal to ensure that it meets the standards of research excellence.
As members can see, our government has already taken significant action. This is why we will not be supporting Bill C-280.
It is important to note that, if enacted, Bill C-280 would require by statute that our government undertake by March 2012 clinical trials on the procedure proposed by Dr. Zamboni. The bill does not specify whether these would be phase I, II or III trials. Surely the sponsor must recognize and realize that due to the legislative process this implementation date would likely come and go before both houses could consider the bill before us today.
It is crucial that we, as legislators, do not inadvertently interfere with the integrity of the clinical trials. We, like MS patients, their caregivers and medical professionals like myself, must respect the steps medical research requires in gathering the best evidence.
More importantly, I am pleased to report that during last month's meeting in Halifax, health ministers from across the country discussed the need for moving forward with phase I and phase II trials. Thanks to last month's announcement, that is exactly what is happening. By conducting rigorous peer review, our government is taking the necessary steps to ensure that the investigation of CCSVI will not have long-term negative repercussions on the health of Canadians living with MS.
Canada is not the only country striving to assist MS patients while also proceeding with appropriate caution. In the United Kingdom, the National Institute for Health and Clinical Excellence has launched a consultation process on venoplasty for CCSVI for MS. Its consultation document explains that the link between CCSVI and MS is not well understood and that research to resolve this uncertainty would be useful. The consultation process was completed in September of this year and will provide guidance to the institute as well as to the U.K.'s National Health Service on the safety and efficacy of CCSVI.
The fact of the matter is there are many unknowns regarding CCSVI angioplasty. We look forward to reviewing the findings from these and other highly credible institutions that are studying CCSVI. That is what the MS Society, prominent members of the medical community, provinces and international health care services have advised.
That said, let there be no doubt that this government shares the determination of MS patients and their families that new developments should be rigorously assessed and researched. It is our shared hope that this research will lead to medically proven, evidence-based procedures to improve the lives of patients with multiple sclerosis and ultimately to finding a cure for MS.